RCS - Creo Medical Group - Appointment of Marco Scarci

Creo MedicalAnnouncement

22/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230622:nRSV5137Da&default-theme=true

RNS Number : 5137D  Creo Medical Group PLC  22 June 2023

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Appointment of Marco Scarci to lead Pulmonary Clinical Advisory Group

Group to help shape and take forward Creo's MicroBlate™ clinical strategy

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces that it has appointed Marco
Scarci as lead of the Company's newly created Pulmonary Clinical Advisory
Group.

 

Marco Scarci, who will provide expert clinical advice and counsel in relation
to the Company's microwave ablation technology, is a highly experienced
London-based Consultant Thoracic Surgeon, specialising in minimally invasive
techniques. His specialist training took place in Italy, Malta, the Essex
Cardiothoracic Centre and Guy's and St Thomas', London. Following a six-month
fellowship in minimally invasive surgery at the University of Toronto, Canada,
Mr Scarci was appointed Consultant Thoracic Surgeon at Papworth Hospital NHS
Foundation Trust, Cambridge.

 

Marco joins Creo as it looks to develop and build on clinical trials to assess
the safe and effective ablation of pre-cancerous and cancerous lesions through
the Company's MicroBlate™ products. Marco's extensive network will enable
him to engage with Kamaptive partners, medical advisors, key opinion leaders
and medical societies to help shape and take forward Creo's microwave ablation
clinical strategy, with a view to maximising the impact the technology can
have on patients around the world.

 

Marco Scarci said of his appointment: "I'm delighted to join Creo Medical and
to help shape an ablation clinical strategy with the aim of demonstrating what
I and many others believe this technology to be - a potential game changer in
the way soft tissue lesions can be treated in future."

 

Craig Gulliford, Chief Executive Officer of Creo Medical, added "We welcome
Marco's vast clinical experience to the team. With one clinical trial for our
lung ablation technology already under way and further trials in the pipeline,
it's fantastic to have such a globally respected mind helping guide us as we
look to maximise the impact of our technology and achieve the best possible
outcomes for patients across multiple indications."

 

 

Enquiries:

 

 Creo Medical Group plc                            www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                +44 (0)1291 606 005

 Cenkos Securities plc                             +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Joint Broker)

 Numis Securities Limited (Joint Broker)           +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                   Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 / Phillip Marriage

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADGGDLDGDDGXB